Blog
RSS FeedPosted by Michael Wonder on 16 Apr 2019
Ribociclib in advanced breast cancer: survival benefits, but also severe side effects
15 April 2019 - In the overall view, an added benefit is not proven. ...
Posted by Michael Wonder on 26 Mar 2019
Numerous G-BA decisions on new medicines - five active substances with considerable added value
22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the ...
Posted by Michael Wonder on 05 Mar 2019
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany
5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...
Posted by Michael Wonder on 14 Feb 2019
Germany agrees on new pharmaceutical bill
13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...
Posted by Michael Wonder on 03 Feb 2019
Erenumab in migraine: indication of a significant added benefit for certain patients
2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...
Posted by Michael Wonder on 23 Jan 2019
Citizens ask - scientists answer: the IQWiG sets four new topics for HTA reports
23 January 2019 - Citizens, patients and medical experts: selection of topics with a sense of proportion ...
Posted by Michael Wonder on 15 Jan 2019
Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival
15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...
Posted by Michael Wonder on 10 Jan 2019
2018 in a nutshell: new edition with facts and graphics from the IQWiG
9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...
Posted by Michael Wonder on 08 Dec 2018
AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit
3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...
Posted by Michael Wonder on 07 Dec 2018
Underuse of innovative medicines in Germany: A justification for government intervention?
6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse. ...
Posted by Michael Wonder on 15 Nov 2018
German health minister calls for faster adoption of biosimilar drugs
14 November 2018 - Germany’s health minister Jens Spahn has called for faster adoption of cheaper copies of biotech drugs ...
Posted by Michael Wonder on 01 Oct 2018
Pertuzumab in early breast cancer: no proof of an additional benefit despite exemplary surrogate validation
1 October 2018 - Effect on disease-free survival too small to conclude on overall survival. ...
Posted by Michael Wonder on 12 Sep 2018
A breakthrough cancer drug has been approved. Now comes the battle over the price.
12 Septemner 2018 - Novartis' breakthrough cancer drug Kymriah has been approved in Europe. Now comes the debate about its ...
Posted by Michael Wonder on 02 Jul 2018
Haemophilia A and sialorrhoea: contemporary comparative therapies not implemented so added benefit not proven
2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity ...
Posted by Michael Wonder on 21 Jun 2018
Confirmatory versus explorative endpoint analysis: decision-making on the basis of evidence available from market authorisation and early benefit assessment for oncology drugs
21 June 2018 - The early benefit assessment of pharmaceuticals in Germany and their preceding market authorisation pursue different objectives. ...